Mycophenolate mofetil (MMF) Clinical Trials

4 actively recruiting trials across 3 locations

Also known as: CellCept

Pipeline

Phase 1: 1Phase 2: 3

Top Sponsors

University of Nebraska1
Stanford University1
Nanjing University School of Medicine1
Hackensack Meridian Health1

Indications

Cancer3
Lupus Nephritis (LN)1
Graft-versus-Host Disease (GVHD)1
Allogeneic Stem Cell Transplant Recipient1
Systemic Lupus Erythematosus (SLE)1

Other1 trial

The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment

Phase 2

Stanford, California1 trial

Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft

Stanford University

Phase 1

Washington D.C., District of Columbia1 trial

Fludarabine and Intermediate-dose TBI Followed by PTCy in Patients Undergoing Allo Transplant for Heme Malignancies

Lombardi Comprehensive Cancer Center at Georgetown University Medical Center

Phase 2

Omaha, Nebraska1 trial

Optimizing GVHD Prophylaxis After Allogeneic Hematopoietic Cell Transplantation

University of Nebraska Medical Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.